Nuclear and Near-Infrared (NIR) Imaging in Melanoma
|ClinicalTrials.gov Identifier: NCT01295931|
Recruitment Status : Completed
First Posted : February 15, 2011
Last Update Posted : October 7, 2015
- To determine the feasibility of using microdose amounts of near-infrared (NIR) fluorescent contrast agent to image tumor-draining and contralateral lymphatics in melanoma patients prior to standard-of-care sentinel lymph node biopsy OR completion lymph node dissection (axillary or inguinofemoral)
- To determine the feasibility of using nonradioactive optical imaging techniques with indocyanine green (ICG) as a fluorescent contrast agent to characterize lymphatic architecture and function by correlating the observed lymphatic structure and function with tumor and nodal status as determined from standard-of-care immunohistochemical evaluation.
|Condition or disease||Intervention/treatment||Phase|
|Melanoma||Drug: Indocyanine Green (IC-Green) Procedure: Imaging||Phase 1|
Show Detailed Description
|Study Type :||Interventional (Clinical Trial)|
|Actual Enrollment :||20 participants|
|Intervention Model:||Single Group Assignment|
|Masking:||None (Open Label)|
|Official Title:||Diagnostic Nodal Staging for Melanoma With Nuclear and Near-Infrared (NIR) Molecular Optical Imaging|
|Study Start Date :||February 2011|
|Primary Completion Date :||October 2014|
|Study Completion Date :||October 2014|
Experimental: IC-Green + Imaging
Indocyanine Green (IC-Green) Injections + Imaging
Drug: Indocyanine Green (IC-Green)
5 intradermal injections, 25 µg IC-Green in 0.1 mL of saline, in locations on the extremity (i.e. arm or leg) correlating with the tumor draining nodal basin to begin. Corresponding injections performed on the contralateral limbs.
Other Name: ICGProcedure: Imaging
Nonradioactive optical imaging with indocyanine green as a fluorescent contrast agent prior to sentinel lymph node biopsy or lymph node surgery.
- Percentage of Nodes Identified by Indocyanine Green (ICG) Among All Resected Lymph Nodes [ Time Frame: 18-24 hours after procedure ]Procedure feasible if 18 out of 24 evaluable patients have 80% or more nodes identified by ICG among all resected nodes. Descriptive analyses performed to report the mean percentage and its 95% confidence interval of the nodes identified by ICG among the total resected nodes of all evaluable subjects. Outcome will be tabulated by age, different tumor stage, nodal status, and body mass index.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01295931
|United States, Texas|
|University of Texas MD Anderson Cancer Center|
|Houston, Texas, United States, 77030|
|Principal Investigator:||Janice N. Cormier, MD, MPH, BS||M.D. Anderson Cancer Center|